186 related articles for article (PubMed ID: 32392820)
1. Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
Vorobyeva A; Konovalova E; Xu T; Schulga A; Altai M; Garousi J; Rinne SS; Orlova A; Tolmachev V; Deyev S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392820
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
[TBL] [Abstract][Full Text] [Related]
3. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
[TBL] [Abstract][Full Text] [Related]
4. Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.
Deyev SM; Xu T; Liu Y; Schulga A; Konovalova E; Garousi J; Rinne SS; Larkina M; Ding H; Gräslund T; Orlova A; Tolmachev V; Vorobyeva A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298801
[TBL] [Abstract][Full Text] [Related]
5. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
[TBL] [Abstract][Full Text] [Related]
6. Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with
Tolmachev V; Bodenko V; Orlova A; Schulga A; Deyev SM; Vorobyeva A
Oncol Lett; 2023 Jan; 25(1):12. PubMed ID: 36478911
[TBL] [Abstract][Full Text] [Related]
7. DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker.
Babaee N; Talebkhan Garoosi Y; Karimipoor M; Davami F; Bayat E; Safarpour H; Mahboudi F; Barkhordari F
Mol Biol Rep; 2020 Oct; 47(10):7323-7331. PubMed ID: 32979162
[TBL] [Abstract][Full Text] [Related]
8. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
9. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.
Xu T; Vorobyeva A; Schulga A; Konovalova E; Vorontsova O; Ding H; Gräslund T; Tashireva LA; Orlova A; Tolmachev V; Deyev SM
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439094
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.
Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
[TBL] [Abstract][Full Text] [Related]
12. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
13. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
[TBL] [Abstract][Full Text] [Related]
14. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
15. EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer.
van den Brand D; van Lith SAM; de Jong JM; Gorris MAJ; Palacio-Castañeda V; Couwenbergh ST; Goldman MRG; Ebisch I; Massuger LF; Leenders WPJ; Brock R; Verdurmen WPR
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630661
[TBL] [Abstract][Full Text] [Related]
16. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
[TBL] [Abstract][Full Text] [Related]
19. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
20. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.
Simon M; Stefan N; Borsig L; Plückthun A; Zangemeister-Wittke U
Mol Cancer Ther; 2014 Feb; 13(2):375-85. PubMed ID: 24184633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]